NIH R01 · 2025
Project Summary Currently, preventative chemotherapy strategies with Praziquantel (PZQ) are the mainstay of treatment for schistosomiasis, with “mass drug administration” (MDA) delivered annually in schools or communities. The primary cause of severe morbidity and death due to intestinal schistosomiasis is portal fibrosis secondary to intra-hepatic egg deposition with consequent portal hypertension and esophageal varices with high risk of hemorrhage. Importantly, there are no current recommendations globally to identify individuals with earlier stages of hepatic fibrosis while it is still reversible. No trials have examined whether treating more than annually, which leaves a significant…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.